A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
← catalyst calendarNCT02130362 · readout ≤ 1,564 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,446actual
Sites
148
Countries
Bosnia and Herzegovina, Bulgaria, Canada +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2014-08-28 | actual | When the study began enrolling |
| Primary completion | Nov 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2014-05-05 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Primary outcomes
what the primary-completion date above is the date OFNumber of treatment-emergent AESI per 100 PYs of infections and malignancies
measured Up to 10 years
Percentage of subjects with SAEs
measured Up to 10 years
Number of treatment-emergent other AESI per 100 PYs
measured Up to 5 years
Percentage of subjects with other AESI
measured Up to 5 years
Number of subjects with Adverse Events of Special Interest (AESI) of infections, malignancies, and pregnancies
measured Up to 10 years
Number of subjects with other AESI
measured Up to 5 years
Number of treatment-emergent SAEs per 100 patient years (PYs)
measured Up to 10 years
Number of subjects with Serious Adverse Events (SAEs)
measured Up to 10 years
Percentage of subjects with AESI of infections, malignancies, and pregnancies
measured Up to 10 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed